Skip Nav Destination
Close Modal
Update search
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Journal
Article Type
Issue Section
Date
Availability
1-19 of 19
Keywords: Minimal residual disease
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Sort by
Journal Articles
Journal:
Acta Haematologica
Acta Haematol (2024) 147 (1): 22–32.
Published Online: 30 October 2023
...Othman Al-Sawaf Background: The level of minimal residual disease (MRD), often binarized into detectable or undetectable MRD according to certain thresholds, is strongly associated with long-term outcomes after chemo- and chemoimmunotherapy. Summary: Driven by our improved understanding...
Journal Articles
Journal:
Acta Haematologica
Acta Haematol (2023) 146 (5): 349–357.
Published Online: 07 May 2023
.... Results: CD20 positivity was observed in 22.7% of enrolled patients. The analysis of overall and event-free survival showed that white blood cell count ≥50 × 10 9 /L, no ETV6-RUNX1 , day 33 minimal residual disease (MRD) ≥0.1%, and week 12 MRD ≥0.01% were independent risk factors. Meanwhile, in the CD20...
Journal Articles
Boaz Nachmias, Svetlana Krichevsky, Dvora Filon, Ehud Even-Or, Moshe E. Gatt, Revital Saban, Batia Avni, Sigal Grisariu, Shlomzion Aumann, Vladimir Vainstein
Journal:
Acta Haematologica
Acta Haematol (2022) 145 (6): 642–649.
Published Online: 05 August 2022
... of molecular markers for minimal residual disease provides a powerful tool to assess remission and guide clinical decisions. Methods: Newly diagnosed RUNX1-mutated AML patients, designated to intensive chemotherapy-based treatment or nonintensive regimens, were monitored for mutated RUNX1 transcript levels...
Journal Articles
Journal:
Acta Haematologica
Acta Haematol (1991) 85 (1): 1–5.
Published Online: 20 February 2009
... timing for supralethal therapy, it may be possible to achieve cure with greater frequency. Measurement of ‘minimal residual disease’ permits more logical selection of postinduction therapy. 23 02 1990 31 07 1990 20 2 2009 © 1991 S. Karger AG, Basel 1991 Copyright / Drug Dosage...
Journal Articles
Chihiro Shimazaki, Hideo Gotoh, Naritoshi Oku, Tohru Inaba, Satoshi Murakami, Nariaki Oku, Kunihiko Itoh, Yasuaki Ura, Masao Nakagawa, Naohisa Fujita
Journal:
Acta Haematologica
Acta Haematol (1991) 85 (1): 20–25.
Published Online: 20 February 2009
... and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Cytoplasmic immunoglobulin DNA Dual parameter analysis Minimal residual disease Multiple myeloma Acta Haematol...
Journal Articles
Journal:
Acta Haematologica
Acta Haematol (2008) 119 (2): 73–82.
Published Online: 20 February 2008
.... Acute promyelocytic leukemia Children Tretinoin Anthracyclines Minimal residual disease Arsenic trioxide RARα is a member of the retinoic acid (RA) nuclear receptor family that acts as ligand-inducible transcription factor by binding to specific response elements (RARE) at the promoter...
Journal Articles
W. Verbeek, H. König, J. Boehm, D. Kohl, C. Lange, T. Heuer, C. Scheibenbogen, H.-E. Reis, A. Hochhaus, U. Graeven
Journal:
Acta Haematologica
Acta Haematol (2006) 115 (1-2): 109–112.
Published Online: 18 January 2006
... P, Goldman JM: Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: correlations with acute graft versus host disease and relapse. Br J Haematol 1993;84:67–74. 9. Emig M, Sausele S, Wittor H, Weisser A, Reiter A, Willer...
Journal Articles
Journal:
Acta Haematologica
Acta Haematol (2005) 114 (4): 214–220.
Published Online: 02 November 2005
...Shimon Slavin Cumulative clinical experience suggests that immunotherapy may be an effective tool for eradicating tumor cells resistant to maximum tolerated doses of chemotherapy and radiation. Immunotherapy is much more effective when applied at the stage of minimal residual disease, especially...
Journal Articles
Journal:
Acta Haematologica
Acta Haematol (2005) 114 (4): 206–213.
Published Online: 02 November 2005
... transplantation (ASCT) in patients with malignant hematologic disorders. Monitoring of minimal residual disease (MRD) is now recognized as an important diagnostic tool for assessment either of the response to treatments aimed at maximal cytoreduction and the individual risk of relapse. In order to improve cure...
Journal Articles
Journal:
Acta Haematologica
Acta Haematol (2004) 112 (1-2): 85–92.
Published Online: 09 June 2004
... and of technologies to measure these targets. Chronic myeloid leukemia Fluorescence in situ hybridization Imatinib Minimal residual disease Molecular cytogenetics Quantitative RT-PCR 9 6 2004 © 2004 S. Karger AG, Basel 2004 Copyright / Drug Dosage / Disclaimer Copyright: All rights...
Journal Articles
Journal:
Acta Haematologica
Acta Haematol (2004) 112 (1-2): 16–23.
Published Online: 09 June 2004
... and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Stem cell transplantation Chimerism Minimal residual disease PCR Leukemia After allogeneic blood stem cell...
Journal Articles
Journal:
Acta Haematologica
Acta Haematol (2004) 112 (1-2): 34–39.
Published Online: 09 June 2004
.... The extent of reduction in the level of minimal residual disease (MRD) during the first phase of therapy can be exploited for improved risk classification of children with ALL. Current prospective studies test the hypothesis that tailoring treatment to the level of MRD will improve patients’ outcome...
Journal Articles
Martin C. Müller, Tanja Hördt, Peter Paschka, Kirsten Merx, Paul La Rosée, Rüdiger Hehlmann, Andreas Hochhaus
Journal:
Acta Haematologica
Acta Haematol (2004) 112 (1-2): 30–33.
Published Online: 09 June 2004
...Martin C. Müller; Tanja Hördt; Peter Paschka; Kirsten Merx; Paul La Rosée; Rüdiger Hehlmann; Andreas Hochhaus Optimal sample quality is a prerequisite to generate valid data in the detection of minimal residual disease (MRD) in leukemias. Thus, the risk of obtaining ‘false’-negative results...
Journal Articles
Journal:
Acta Haematologica
Acta Haematol (2004) 112 (1-2): 79–84.
Published Online: 09 June 2004
...Daniela Cilloni; Giuseppe Saglio Monitoring of acute leukemia patients during and after treatment for the presence of remaining leukemic cells (minimal residual disease, MRD) has been shown to give major insight into the effectiveness of treatment. However, so far the applicability of this strategy...
Journal Articles
Journal:
Acta Haematologica
Acta Haematol (2004) 112 (1-2): 111–119.
Published Online: 09 June 2004
... is compatible with significant amounts of residual malignant cells. Cytogenetic, molecular and immunological techniques that are more sensitive than morphology are increasingly used to assess and quantify minimal residual disease (MRD). Immunological marker analysis allows the detection of aberrant or unusual...
Journal Articles
Journal:
Acta Haematologica
Acta Haematol (2004) 112 (1-2): 24–29.
Published Online: 09 June 2004
...Luba Trakhtenbrot; Gideon Rechavi; Ninette Amariglio Combined simultaneous analysis of morphology, immunophenotyping and fluorescence in situ hybridization on the same cell offers advantages that may help to disclose the relevance of minimal residual disease (MRD) detection. Morphological analysis...
Journal Articles
Journal:
Acta Haematologica
Acta Haematol (2004) 112 (1-2): 8–15.
Published Online: 09 June 2004
...Dario Campana; Elaine Coustan-Smith Minimal residual disease (MRD) assays are increasingly important in the clinical management of patients with acute leukemia. Among the methods available for monitoring MRD, flow cytometry holds great promise for clinical application because of its simplicity...
Journal Articles
Journal:
Acta Haematologica
Acta Haematol (2004) 112 (1-2): 68–78.
Published Online: 09 June 2004
... mutations but also use these markers for the definition of minimal residual disease (MRD). However, so far the cytogenetically intermediate AML has been lacking suitable markers for PCR-based MRD detection like the fusion genes in the prognostically favourable subgroups. The suitability of the FLT3-LM...
Journal Articles
Yasushi Okoshi, Seiichi Shimizu, Hiroshi Kojima, Naoshi Obara, Harumi Y. Mukai, Takuya Komeno, Yuichi Hasegawa, Naoyoshi Mori, Toshiro Nagasawa
Journal:
Acta Haematologica
Acta Haematol (2001) 105 (1): 45–48.
Published Online: 27 April 2001
... ]. However, the significance of the detection of minimal residual disease (MRD) in this type of AML has not been well established until today. We present here an AML-M1 patient with t(16;21)(p11;q22) treated by allogeneic bone marrow transplantation (BMT), but the leukemia relapsed 9 months after...